Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma [Phase 2]
Phase 2 trial evaluating Anbalcabtagene Autoleucel for relapsed/refractory primary central nervous system lymphoma and diffuse large B-cell …
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) [Phase 3]
Phase 3 study evaluating safety and efficacy of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. The t…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating golcadomide, poseltinib, and rituximab for relapsed/refractory diffuse large B-cell lymphoma, wi…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta [Phase 1]
This Phase 1 trial seeks to optimize lymphodepletion strategies to improve outcomes for patients with diffuse large B-cell lymphoma receivin…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: PD-L1 PET-imaging During CAR T-cell Therapy [Phase 2]
Phase 2 clinical trial update investigating PD-L1 PET imaging during CAR T-cell therapy in diffuse large B-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML [Phase 1, Phase 2]
This clinical trial update describes pediatric patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and diffuse large B-cell…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma [EARLY_Phase 1]
A Phase 1 trial assessing safety and preliminary efficacy of anti-EBV autologous TCR-T cell therapy in relapsed/refractory EBV-positive lymp…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: The TASTY-steering Study [NA]
A clinical trial update indicates that the TASTY-steering Study is currently recruiting for patients with metastatic triple-negative breast …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL [Phase 2]
Phase 2 trial evaluating the combination of pirtobrutinib, lisaftoclax, and rituximab in relapsed/refractory diffuse large B-cell lymphoma, …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
An expanded access program update for axicabtagene ciloleucel (Yescarta) for patients with diffuse large B-cell lymphoma and follicular lymp…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma [Phase 2]
This Phase 2 trial is evaluating the efficacy of axicabtagene ciloleucel in patients with late-relapse diffuse large B-cell lymphoma and is …
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma [Phase 2, Phase 3]
Xinlikang Capsule is being studied in Phase 2 and Phase 3 trials for chemotherapy-induced fatigue and immune disorders in patients with diff…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a glofitamab-based treatment in people with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, …
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial evaluating whether CD34+ cell dose influences absolute lymphocyte count after high-dose therapy and autologous stem c…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating loncastuximab tesirine and rituximab followed by DA-EPOCH-R for high-risk diffuse large B-cell lymphoma. Recruitmen…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as salvage therapy for transplant-elig…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
This clinical trial update reports ongoing recruitment for a study aimed at identifying predictive factors for the efficacy of CD19 CAR-T th…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 2]
This is a Phase 2 study evaluating a triple-drug regimen of glofitamab, polatuzumab vedotin, and zuberitamab in newly diagnosed diffuse larg…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
A recruiting clinical study examining metabolic and immunomic differences in primary central nervous system lymphoma and diffuse large B-cel…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A clinical trial is recruiting to evaluate drug-eluting bead-based transarterial chemoembolization (DEB-TACE) as local salvage therapy for l…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relap…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…